Niacin

Generic Name: Niacin

Brand Names: Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one

Drug Type: Small Molecule

Chemical Formula: C_₆H_₅NO_₂

CAS Number: 59-67-6

Unique Ingredient Identifier: 2679MF687A

Background: Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

Indication: Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.

Associated Conditions: Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia

Associated Therapies: Dietary supplementation

Clinical Trials

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

Phase 4

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2008-01-10

Last Posted Date: 2011-09-14

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 43

Registration Number: NCT00590629

Locations: 🇺🇸
CSMC, Los Angeles, California, United States

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

Phase 2

Terminated

Conditions: Central Retinal Vein Occlusion
Branch Retinal Vein Occlusion

Interventions: Drug: nicotinic acid

First Posted Date: 2007-07-12

Last Posted Date: 2019-11-13

Lead Sponsor: Palo Alto Medical Foundation

Target Recruit Count: 36

Registration Number: NCT00500045

Locations: 🇺🇸
Palo Alto Medical Foundation Department of Ophthalmology, Palo Alto, California, United States

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

Phase 2

Completed

Conditions: Retinal Vein Occlusion

Interventions: Drug: Nicotinic acid
Drug: Prednisolone acetate

First Posted Date: 2007-06-27

Last Posted Date: 2018-12-21

Lead Sponsor: Palo Alto Medical Foundation

Target Recruit Count: 63

Registration Number: NCT00493064

Locations: 🇺🇸
Palo Alto Medical Foundation Department of Ophthalmology, Palo Alto, California, United States

Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)

Phase 3

Completed

Conditions: Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions: Drug: niacin (+) laropiprant

First Posted Date: 2007-05-28

Last Posted Date: 2015-03-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1216

Registration Number: NCT00479388

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)

Phase 3

Completed

Conditions: Hyperlipidemia
Mixed Dyslipidemia

Interventions: Drug: Niacin ER/Simvastatin Tablets
Drug: atorvastatin

First Posted Date: 2007-04-24

Last Posted Date: 2011-06-13

Lead Sponsor: Abbott

Target Recruit Count: 199

Registration Number: NCT00465088

High-Density Lipoprotein (HDL) Treatment Study

Not Applicable

Completed

Conditions: Coronary Arteriosclerosis
Hypoalphalipoproteinemias
Genetic Diseases, Inborn

First Posted Date: 2007-04-09

Last Posted Date: 2008-06-04

Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Target Recruit Count: 19

Registration Number: NCT00458055

Locations: 🇨🇦
MUHC-Royal Victoria Hospital, Montreal, Quebec, Canada

Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)

Phase 2

Conditions: Coronary Artery Disease

First Posted Date: 2007-02-05

Last Posted Date: 2007-02-05

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 80

Registration Number: NCT00431145

Locations: 🇩🇪
University of Munich, Munich, Germany

Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Phase 4

Terminated

Conditions: Atherosclerosis

Interventions: Drug: extended release niacin
Drug: ezetimibe

First Posted Date: 2006-11-09

Last Posted Date: 2009-06-17

Lead Sponsor: Walter Reed Army Medical Center

Target Recruit Count: 400

Registration Number: NCT00397657

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸
Washington Adventist Hospital, Takoma Park, Maryland, United States